There they went. While no one may take boiler plate seriously, here is what they said in June. Aside from legitimate doubts about their success with their magic pill, we have good reason to suspect the toilet will be flushed soon.
"At June 30, 2018, the Company had working capital of approximately $14.9 million, an accumulated deficit of approximately $58.9 million, and cash and cash equivalents of approximately $16.3 million. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and pre-clinical testing, and commercialization of the Company’s products will require significant financing. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.
News 
Market Data 
Discover 
